Jorge E Toblli1, Federico Di Gennaro2, Carlos Rivas2. 1. Hospital Alemán, School of Medicine, University of Buenos Aires, Av. Pueyrredon 1640, (1118) Buenos Aires, Argentina. Electronic address: jorgetoblli@fibertel.com.ar. 2. Hospital Alemán, School of Medicine, University of Buenos Aires, Av. Pueyrredon 1640, (1118) Buenos Aires, Argentina.
Abstract
BACKGROUND: Treatment of iron deficiency helps to improve cardiac and renal function in patients with chronic heart failure. However, the mechanism by which this occurs is currently unclear. METHODS: We undertook a double-blind, randomised, placebo-controlled study of intravenous iron sucrose treatment (200mg/mL weekly for five weeks) in patients with chronic heart failure, chronic kidney disease and iron-deficiency anaemia receiving optimal treatment for chronic heart failure (N=60). Markers of disease severity, iron status, anaemia and inflammation were measured during a six-month follow-up period, and evaluation of echocardiographic parameters was performed at baseline and six months after treatment. RESULTS: At six months after treatment initiation, intravenous iron was associated with reduced severity of the symptoms of chronic heart failure and improved renal function (both p<0.001 versus control). Also, ferritin and transferrin saturation levels were increased, as were haemoglobin levels, whereas inflammatory markers were reduced (all p<0.001 versus control). Left ventricular systolic and diastolic diameters were increased and improved left ventricular function correlated with iron status in patients receiving intravenous iron but not patients in the control group. CONCLUSIONS: Intravenous iron treatment was associated with improved myocardial functional parameters and cardiac dimensions in patients with anaemia and chronic kidney disease.
RCT Entities:
BACKGROUND: Treatment of iron deficiency helps to improve cardiac and renal function in patients with chronic heart failure. However, the mechanism by which this occurs is currently unclear. METHODS: We undertook a double-blind, randomised, placebo-controlled study of intravenous iron sucrose treatment (200mg/mL weekly for five weeks) in patients with chronic heart failure, chronic kidney disease and iron-deficiency anaemia receiving optimal treatment for chronic heart failure (N=60). Markers of disease severity, iron status, anaemia and inflammation were measured during a six-month follow-up period, and evaluation of echocardiographic parameters was performed at baseline and six months after treatment. RESULTS: At six months after treatment initiation, intravenous iron was associated with reduced severity of the symptoms of chronic heart failure and improved renal function (both p<0.001 versus control). Also, ferritin and transferrin saturation levels were increased, as were haemoglobin levels, whereas inflammatory markers were reduced (all p<0.001 versus control). Left ventricular systolic and diastolic diameters were increased and improved left ventricular function correlated with iron status in patients receiving intravenous iron but not patients in the control group. CONCLUSIONS: Intravenous iron treatment was associated with improved myocardial functional parameters and cardiac dimensions in patients with anaemia and chronic kidney disease.
Authors: Aslihan Yerlikaya; Mustafa C Bulbul; Baris Afsar; Tuncay Dagel; Gamze Aslan; Luminita Voroneanu; Dimitire Siriopol; Adrian Covic; Mehmet Kanbay Journal: Int Urol Nephrol Date: 2017-09-22 Impact factor: 2.370
Authors: Gema Miñana; Ingrid Cardells; Patricia Palau; Pau Llàcer; Lorenzo Fácila; Luis Almenar; Maria Pilar López-Lereu; Jose V Monmeneu; Martina Amiguet; Jessika González; Alicia Serrano; Vicente Montagud; Raquel López-Vilella; Ernesto Valero; Sergio García-Blas; Vicent Bodí; Rafael de la Espriella-Juan; Juan Sanchis; Francisco J Chorro; Antoni Bayés-Genís; Julio Núñez Journal: Clin Cardiol Date: 2018-06-05 Impact factor: 2.882
Authors: Iain C Macdougall; Claire White; Stefan D Anker; Sunil Bhandari; Kenneth Farrington; Philip A Kalra; John J V McMurray; Heather Murray; Retha Steenkamp; Charles R V Tomson; David C Wheeler; Christopher G Winearls; Ian Ford Journal: Am J Nephrol Date: 2018-10-10 Impact factor: 3.754
Authors: Meaghan Lunney; Marinella Ruospo; Patrizia Natale; Robert R Quinn; Paul E Ronksley; Ioannis Konstantinidis; Suetonia C Palmer; Marcello Tonelli; Giovanni Fm Strippoli; Pietro Ravani Journal: Cochrane Database Syst Rev Date: 2020-02-27